PIN Pharma Announces Interim Results of Phase 1 Study with PIN-2

NEW YORK--(BUSINESS WIRE)-- PIN Pharma today announced interim results of its Phase I clinical trial in all comers with solid tumors for its next generation novel immunomodulator, PIN-2.

Colin Bier, CEO indicated that, “We are pleased that PIN-2 was well-tolerated, safe and demonstrated pharmacologic activity. There were no serious or immune-related adverse events. When completed, this study should support further clinical trials for the safe and efficacious use of PIN-2 as an immunomodulator in cancer therapy.”

This first-in-human, proof-of-concept and safety study is being conducted in oncology patients with established solid tumors by PIN Pharma’s wholly owned Australian subsidiary, PIN Pharma Pty Ltd. The study is designed to show changes in the human immune system utilizing biomarkers that demonstrates PIN-2’s ability to link the innate and adaptive immune systems by de novo stimulation and reprogramming of blood monocytes to become activated APCs which ultimately stimulate effector T-cell (CD8+) activity.

About PIN Pharma, Inc.

PIN Pharma is a clinical stage venture backed immunotherapy company focused on the development of PINS (precision immune stimulants). The Company’s technology is predicated upon modulating the innate immune response to overcome cancer-mediated immune suppression. Pin Pharma is pursuing immune oncology as its first indication albeit PINS have potential in other therapeutic areas.


For more information about PIN Pharma and PIN-2, contact Mark Smith, CFO ( or Colin Bier, CEO ( at PIN Pharma, Inc., 3960 Broadway, Suite 620, New York, NY, or call 212-543-2583


PIN Pharma, Inc.
Mark Smith, CFO
Colin Bier, CEO


Source: PIN Pharma, Inc.

Back to news